高脂血症
单克隆抗体
医学
肺癌
疾病
抗体
内科学
免疫学
内分泌学
糖尿病
作者
Laura Pérez Alonso,Raquel Cervera Calero,María A. Sevilla,Miguel Ángel Moreno Palanco,Jorge Francisco Gómez Cerezo
标识
DOI:10.1016/j.arteri.2022.12.003
摘要
Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI